For decades, chronic traumatic encephalopathy (CTE)—the degenerative brain disease linked to repeated head injuries in contact sports and military service—could be definitively identified only after a patient’s death. This diagnostic gap has left countless people facing symptoms of memory loss, extreme mood swings, and cognitive decline waiting years for clarity. Now, a team at Washington University in St. Louis has unveiled findings that could mark the beginning of major change in how CTE is detected and managed during life.

On November 14, 2026, Associated Press reported that the university’s researchers had found unusually elevated levels of a biomarker known as eMTBR-tau243 in the brain sample of a patient confirmed, by autopsy, to have advanced-stage CTE but not Alzheimer’s disease. Their work, conducted in a small cohort, included blood analysis of 11 individuals previously diagnosed with CTE, which also showed significantly higher concentrations of this tau protein fragment compared to healthy control subjects. The hope is that such biomarkers might one day serve as a crucial signal to distinguish living patients most at risk for CTE.

Complexities and Caveats

The study’s authors and outside experts emphatically stress that these are preliminary findings. Elevated tau proteins are not exclusive to CTE; they are common to several neurodegenerative disorders including Alzheimer’s, making any single marker unlikely to offer conclusive evidence on its own. Furthermore, the data so far offers little help for detecting early-stage disease: the eMTBR-tau243 biomarker was primarily present in advanced cases, suggesting it may aid in confirming diagnosis rather than enabling early intervention.

Currently, CTE can only be diagnosed through post-mortem brain autopsy, where neuropathologists look for abnormal tau deposits and patterns of brain damage specific to the condition. Continued research is underway globally to develop imaging and blood-based diagnostics that could provide answers while patients are still alive—a challenge that has vexed the field for years.

The Toll of Repeated Head Impacts

CTE is most commonly found in athletes who’ve sustained repeated head impacts through contact sports, as well as in military personnel exposed to blast injuries. Its difficult-to-predict progression, wide range of symptoms, and complex interplay with other neurodegenerative diseases make it a focus of intense scientific and public attention. But to date, the lack of reliable in-life diagnosis has hindered both treatment options and the ability to track the true prevalence of CTE in the population.

The Washington University team’s findings are “promising but require validation in much larger studies,” according to the Associated Press and experts not involved in the project. Further research must demonstrate that the eMTBR-tau243 biomarker can consistently distinguish CTE from other conditions across diverse patient populations and at earlier stages of disease.

Looking Forward

While no immediate clinical application can be expected, this research marks a tentative step toward an urgent goal: giving living individuals clarity about the risks they face and the conditions they may be developing. For now, the medical advice for those concerned—especially former athletes and veterans—is unchanged: consult a physician for evaluation and symptom management. But as the search for a diagnostic breakthrough continues, each incremental discovery moves science closer to answers for families, patients, and the organizations responsible for their care.